ResApp Health Limited
(ASX:RAP) has announced it has received institutional review board approval at the Massachusetts General Hospital for its SMARTCOUGH-C study.
The SMARTCOUGH-C study will evaluate the success of the ResAppDx software in using cough sounds to diagnose childhood pneumonia and respiratory conditions
If successful, the technology could be delivered via smartphone, improving patient management and increasing access to healthcare at a reduced cost.
The details of the trial will be made available on the US National Institutes of Health clinical trials database.
ResApp Health Limited reported a net loss of $3.2 million at 30 June 2016.
